A01K2227/108

MESENCHYMAL STEM CELL SHEET AND USE THEREOF

Provided is a method for treating diseases related to cardiac tissue damage or cardiac insufficiency in a subject. The method includes the step of locally applying a mesenchymal stem cell sheet such as an umbilical cord mesenchymal stem cell sheet to the heart of the subject. Also provided are related use and compositions of the mesenchymal stem cell sheet.

PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME

A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.

COMPOSITION FOR SIMULTANEOUSLY MODIFYING AMINO ACIDS OF SITE 736 AND SITE 738 OF PAPN GENE AND APPLICATION THEREOF
20230062272 · 2023-03-02 ·

Provided are compositions for simultaneously modifying amino acids of site 736 and site 738 of pAPN gene and application thereof. An sgRNA set specifically recognizing porcine pAPN gene can recognize sequences near amino acids of site 736 and site 738 of pAPN gene, and has strong specificity. On this basis, in combination with a composition consisting of a cleavage protein and a double-stranded donor sequence, simultaneous modification of amino acids of site 736 and site 738 of the pAPN gene can be realized. Under editing of the composition, the amino acids of site 736 and site 738 of the pAPN gene are modified precisely and effectively, which can prevent normal expression of other amino acids of the pAPN gene from being damaged or changed. Therefore, it can resist TGEV infection, and also can retain the physiological activity function of the pAPN protein to the maximum extent.

Methods for increasing genetic progress in a line or breed of swine using sex-selected sperm cells
11653635 · 2023-05-23 · ·

The invention relates to methods of increasing the genetic progress of a line, breed or herd of swine through the use of sex-selected sperm cells in artificial insemination techniques. The invention also encompasses methods of artificially inseminating a swine via deep intrauterine catheter or via a laparoscopic procedure, which allow the use of reduced doses of sex-selected sperm cells.

PRIMATIZED RODENT
20230112372 · 2023-04-13 ·

A primatized rodent or swine, and methods of making and using the primatized rodent or swine, are provided.

TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES

Disclosed are recombinant meganucleases engineered to bind and cleave a recognition sequence present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in a method for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.

Genetically modified pig cells with an inactivated Etv2 gene

Described herein is a method for producing a chimeric non-human animal expressing a human ETV2 gene comprising: a) generating an ETV2 null non-human animal cell, wherein both copies of the non-human ETV2 gene carry a mutation that prevents production of functional ETV2 protein in said non-human animal; b) creating an ETV2 null non-human blastocyst by somatic cell nuclear transfer comprising fusing a nucleus from said ETV2 null non-human animal cell of a) into an enucleated non-human oocyte and activating said oocyte to divide so as to form an ETV2 null non-human blastocyst; c) introducing human stem cells into the ETV2 null non-human blastocyst of b); and d) implanting said blastocyst from c) into a pseudopregnant surrogate non-human animal to generate a chimeric non-human animal expressing human ETV2.

GRNA FOR KNOCKING OUT PIG XENOANTIGEN GENE, AND APPLICATION THEREOF
20230174983 · 2023-06-08 ·

Provided is gRNA specifically targeting β4GalNT2 gene. The gRNA specifically binds to the nucleotide sequence shown in any one of SEQ ID NOs. 1 and 2. Also provided are an animal model constructed using the gRNA, and an application thereof in the field of biomedicine.

ORGAN FOR TRANSPLANTATION AND ORGAN STRUCTURE

An organ for transplantation having a kidney, a ureter, and a urinary bladder and an organ structure in which a first ureter, a first urinary bladder, a second ureter and a second urinary bladder are sequentially connected to a kidney can produce urine and excrete the produced urine, and thus is useful for transplantation.

Double knockout (GT/CMAH-KO) pigs, organs and tissues

The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional αGAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.